

**DR. REDDY'S LABORATORIES LIMITED**  
**PART I : STATEMENT OF UNAUDITED STANDALONE RESULTS FOR THE QUARTER ENDED 30 JUNE 2012**

All amounts in Indian Rupees lakhs, except share data

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.12 (Unaudited)	31.03.12 (Audited)	30.06.11 (Unaudited)	31.03.12 (Audited)
<b>1</b>	<b>Income from operations</b>				
	a) Net sales / income from operations (Net of excise duty)	174,755	174,871	167,571	660,378
	b) License fees and service income	3,646	1,667	807	6,399
	c) Other operating income	2,053	2,292	1,318	7,193
	<b>Total income from operations (net)</b>	<b>180,454</b>	<b>178,830</b>	<b>169,696</b>	<b>673,970</b>
<b>2</b>	<b>Expenses</b>				
	a) Cost of materials consumed	50,528	52,603	38,721	179,201
	b) Purchase of stock-in-trade	9,003	8,530	7,408	30,763
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7,140)	462	(3,146)	(10,476)
	d) Research and development expenses, net	14,025	16,744	11,911	58,129
	e) Employee benefits expense	26,095	23,596	21,110	86,614
	f) Selling expenses	19,573	14,502	13,928	62,506
	g) Provision for decline in the value of long-term investments	-	19,248	-	19,248
	h) Other expenditure	40,569	23,885	18,588	93,768
	i) Depreciation and amortisation	7,312	8,395	6,893	30,115
	<b>Total expenses</b>	<b>159,965</b>	<b>167,965</b>	<b>115,413</b>	<b>549,868</b>
<b>3</b>	<b>Profit from operations before other income, finance costs and exceptional items (1 - 2)</b>	<b>20,489</b>	<b>10,865</b>	<b>54,283</b>	<b>124,102</b>
4	Other income	3,040	26,288	5,554	8,178
<b>5</b>	<b>Profit from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>23,529</b>	<b>37,153</b>	<b>59,837</b>	<b>132,280</b>
6	Finance costs	1,722	1,567	1,524	6,362
<b>7</b>	<b>Profit from ordinary activities after finance costs but before exceptional items (5 - 6)</b>	<b>21,807</b>	<b>35,586</b>	<b>58,313</b>	<b>125,918</b>
8	Exceptional items	-	-	-	-
<b>9</b>	<b>Profit from ordinary activities before tax (7 - 8)</b>	<b>21,807</b>	<b>35,586</b>	<b>58,313</b>	<b>125,918</b>
10	Tax expense	4,041	14,407	12,908	34,682
<b>11</b>	<b>Net Profit from ordinary activities after tax (9 - 10)</b>	<b>17,766</b>	<b>21,179</b>	<b>45,405</b>	<b>91,236</b>
12	Extra-ordinary items	-	-	-	-
<b>13</b>	<b>Net profit for the period / year (11 - 12)</b>	<b>17,766</b>	<b>21,179</b>	<b>45,405</b>	<b>91,236</b>
14	Paid - up equity share capital (face value Rs.5/- each)	8,490	8,478	8,474	8,478
15	Reserves (excluding revaluation reserve)				663,317
<b>16</b>	<b>Earnings per share for the period (in Rupees) per Rs.5/- share</b>				
	a) Before Extra-ordinary items				
	- Basic	10.47	12.49	26.82	53.83
	- Diluted	10.41	12.43	26.65	53.56
	b) After Extra-ordinary items				
	- Basic	10.47	12.49	26.82	53.83
	- Diluted	10.41	12.43	26.65	53.56
		(Not annualised)	(Not annualised)	(Not annualised)	

**DR. REDDY'S LABORATORIES LIMITED**

**PART II : SELECTED INFORMATION FOR THE QUARTER ENDED 30 JUNE 2012**

**A PARTICULARS OF SHAREHOLDING**

	Particulars	Quarter ended		Year ended	
		30.06.12	31.03.12	30.06.11	31.03.12
<b>1</b>	<b>Public share holding*</b>				
	- Number of shares (Face value Rs.5/- each)	97,877,295	97,627,569	93,828,201	97,627,569
	- Percentage of share holding	57.64	57.57	55.36	57.57
<b>2</b>	<b>Promoters and promoter group Shareholding</b>				
	a) Pledged/Encumbered				
	- Number of shares	-	-	2,100,000	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	4.84	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	1.24	-
	b) Non-encumbered				
	- Number of shares	43,417,812	43,417,812	41,317,812	43,417,812
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	95.16	100.00
	- Percentage of shares (as a % of the total share capital of the company)	25.57	25.61	24.38	25.61

\*Public Share Holding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders)

**B INVESTOR COMPLAINTS**

Pending at the beginning of the quarter	Nil
Received during the quarter	4
Disposed of during the quarter	4
Remaining unresolved at the end of the quarter	Nil

**Segment Information**

All amounts in Indian Rupees lakhs, except share data

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.12	31.03.12	30.06.11	31.03.12
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>Segment wise revenue, results and capital employed:</b>				
	<b>Segment revenue :</b>				
	a) Pharmaceutical Services and Active Ingredients	57,019	79,855	52,900	259,069
	b) Global Generics	133,901	116,564	126,833	468,035
	c) Proprietary Products	2,779	59	36	189
	<b>Total</b>	<b>193,699</b>	<b>196,478</b>	<b>179,769</b>	<b>727,293</b>
	Less: Inter segment revenue	13,100	17,694	9,293	53,364
	Add : Other unallocable Income	2,895	26,334	4,774	8,219
	<b>Total income</b>	<b>183,494</b>	<b>205,118</b>	<b>175,250</b>	<b>682,148</b>
<b>2</b>	<b>Segment results :</b>				
	Profit / (loss) before tax and interest from each segment				
	a) Pharmaceutical Services and Active Ingredients	6,039	15,486	3,531	48,602
	b) Global Generics	35,369	24,679	59,589	157,976
	c) Proprietary Products	(1,514)	(4,489)	(2,797)	(16,800)
	<b>Total</b>	<b>39,894</b>	<b>35,676</b>	<b>60,323</b>	<b>189,778</b>
	Less: (i) Interest	1,722	1,567	1,524	6,362
	(ii) Other un-allocable expenditure, net	16,365	(1,477)	486	57,498
	<b>Total profit before tax</b>	<b>21,807</b>	<b>35,586</b>	<b>58,313</b>	<b>125,918</b>
<b>3</b>	<b>Capital Employed :</b>				
	a) Pharmaceutical Services and Active Ingredients	208,866	203,180	181,954	203,180
	b) Global Generics	299,262	272,931	311,882	272,931
	c) Proprietary Products	(1,736)	(1,754)	866	(1,754)
	d) Unallocated	173,113	197,438	154,027	197,438
	<b>Total</b>	<b>679,505</b>	<b>671,795</b>	<b>648,729</b>	<b>671,795</b>

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics.

**Notes:**

- The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 19 July 2012.
- The results for the quarter ended 30 June 2012 have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon.
- The figures of the earlier periods have been re-grouped to be in conformity with the new format prescribed under Clause 41 of the listing agreement.

By order of the Board  
For Dr. Reddy's Laboratories Limited

Place: Hyderabad  
Date: 19 July 2012

Satish Reddy  
Managing Director & Chief Operating Officer